Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2952)	7/14/2010 1:43:05 PM
From: Jibacoa	Respond to of 3722

MYGN was up 1.285 but it is down 0.06% at present.<g> Volume is low about 1/5 of its ADV bigcharts.marketwatch.com But MYGN seems to have found support at the $14.30 level and may want to test the resistance at $17.25 and even close some of its May 5 DG MYGN has 4Qs of better revenues, albeit the earnings in the last 2Qs have been lower.<g> The EE for 2010 & 2011 are around $1.32 & $1.19 vs. $1.38 in 2009 But MYGN has NLTD good +CF and institutional following. In May it announced that it planned to repurchase $100M worth of its stock.<g> In spite of the problem with the court decision on the BRCA patents and the recent "downgrade" by an 'analyst' at JPM it seems that the R/R isn't bat at present levels.<g> bigcharts.marketwatch.com Bernard